Announcement Under Irish Takeover Rules
1:12 PM ET, 10/30/2015 - PR Newswire
DUBLIN, Oct. 30, 2015 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) (the "Company") confirms that, as of the close of business on October 28, 2015, the Company's issued share capital, excluding treasury shares, consisted of 394,135,739 ordinary shares, par value US$0.0001 per share (the "Ordinary Shares") and 5,060,000 5.5% mandatory convertible preferred shares, Series A, par value US$0.0001 per share (the "Preferred Shares"). The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00BY9D5467 and of the Preferred Shares is IE00BY9D6T89.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The Company confirms that, as of the close of business on October 28, 2015, there were outstanding 1,350,467 restricted share units (the "Restricted Share Units") and 10,763,384 options to purchase Ordinary Shares (the "Share Options") granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price.
The Company also confirms that, as of the close of business on October 28, 2015, there were outstanding performance share units (the "Performance Share Units") entitling holders to receive 641,107 Ordinary Shares upon vesting, assuming satisfaction of the applicable performance criteria at targeted performance.
About AllerganAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
1:12 PM ET, 10/30/2015 - PR Newswire
DUBLIN, Oct. 30, 2015 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) (the "Company") confirms that, as of the close of business on October 28, 2015, the Company's issued share capital, excluding treasury shares, consisted of 394,135,739 ordinary shares, par value US$0.0001 per share (the "Ordinary Shares") and 5,060,000 5.5% mandatory convertible preferred shares, Series A, par value US$0.0001 per share (the "Preferred Shares"). The International Securities Identification Number (ISIN) of the Ordinary Shares is IE00BY9D5467 and of the Preferred Shares is IE00BY9D6T89.
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO
The Company confirms that, as of the close of business on October 28, 2015, there were outstanding 1,350,467 restricted share units (the "Restricted Share Units") and 10,763,384 options to purchase Ordinary Shares (the "Share Options") granted by the Company. Upon vesting, each Restricted Share Unit entitles the holder to receive one Ordinary Share and each Share Option entitles the holder to purchase one Ordinary Share at the applicable exercise price.
The Company also confirms that, as of the close of business on October 28, 2015, there were outstanding performance share units (the "Performance Share Units") entitling holders to receive 641,107 Ordinary Shares upon vesting, assuming satisfaction of the applicable performance criteria at targeted performance.
About AllerganAllergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.
For more information, visit Allergan's website at www.allergan.com.
FE) (the "Company") confirms that, at the close of business on October 29, 2015, its issued share capital, excluding treasury shares, is comprised of 6,172,660,972 shares of common stock having a par value of $0.05 per share (the "Common Stock"), and 663shares of convertible perpetual preferred stock having no par value (the “Preferred Stock"), which shares of Preferred Stock are convertible into a total of 1,707,281 shares of Common Stock.